Sm153EDTMPBonePainQC

Sm-153 EDTMP Bone Pain QC — Quality control of Sm-153 EDTMP for bone pain therapy

ℹ️ Utility checks critical parameters of Sm-153 EDTMP:

• Radiochemical purity (≥95%)
• Free samarium (≤5%)
• Eu-154 impurity (<0.001%) — CRITICAL!
• pH, osmolality, specific activity

⚠️ CRITICAL: Eu-154 (T½=8.6 years) creates lifelong radiation burden!

Sm-153 EDTMP is used for palliative therapy of bone pain.

Drug is similar to Tc-99m MDP in mechanism of bone accumulation.

Usage

Sm153EDTMPBonePainQC.exe → demo mode (console output)

Sm153EDTMPBonePainQC.exe input.csv output.json → evaluate your data

Input format

BatchNumber,RadiochemicalPurityPercent,FreeSamariumPercent,pH,SpecificActivityMBq_per_mg,EndotoxinsEU_per_mL,SterilityTest,ActivityMBq,RadionuclidicPurityPercent,Eu154ImpurityPercent,Osmolality_mOsm_per_kg

Example

SM153-EDTMP-2026-001,99.0,0.5,7.0,1000.0,10.0,0,2000.0,99.95,0.0005,300.0

— WHY IS THIS NEEDED?

Sm-153 EDTMP (Quadramet) is drug for palliative therapy of bone metastasis pain.

• Sm-153 has 46.3-hour half-life and emits medium-energy beta particles.
• EDTMP (ethylenediaminetetramethylenephosphonic acid) ensures strong binding to bone hydroxyapatite.
• Produced by neutron activation of enriched Sm-152 in reactor.
• Requires high radiochemical purity to avoid accumulation in liver and spleen.

⚠️ CRITICAL:

• Radiochemical purity ≥95% — guarantee of specific accumulation in bones.
• Free samarium ≤5% — free ions accumulate in reticuloendothelial system (liver, spleen).
• Eu-154 impurity <0.001% — Eu-154 is byproduct of activation and has long half-life (8.6 years).
• Specific activity must be high for therapeutic efficacy.
• pH 6.0-8.0 — physiological range.
• Osmolality 250-350 mOsm/kg — isotonicity.
• Endotoxins <175 EU/mL — standard for parenteral drugs.
• Sterility — MANDATORY.

Key features

• Strict control of Eu-154 impurity characteristic of reactor production.
• Assessment of free samarium content, critical for biodistribution.
• Specific activity check for therapeutic effectiveness.
• Compliance with GMP and Pharmacopoeia requirements for Sm-153 radiopharmaceuticals.
• Comprehensive safety check (endotoxins, sterility, pH, osmolality).

Critical parameters

• Radiochemical purity: ≥95.0%
• Free samarium: ≤5.0%
• Radionuclidic purity: ≥99.9%
• Eu-154 impurity: <0.001%
• Specific activity: ≥500 MBq/mg
• pH: 6.0–8.0
• Osmolality: 250–350 mOsm/kg
• Endotoxins: <175 EU/mL
• Sterility: no growth

💡 Usage tips:

1. Radiochemical purity determined by TLC (silica gel/citrate buffer).

2. Eu-154 impurity controlled by gamma spectrometry.

3. Drug is stable for several days due to strong Sm-EDTMP complex.

4. Sm-153 also emits 103 keV gamma quantum, allowing distribution imaging.

5. Therapeutic effect usually occurs 1-2 weeks after administration.

⚠️ Note: Sm-153 EDTMP is alternative to Sr-89 and Ra-223 for palliative care. Its advantage is shorter half-life, which reduces radiation burden on staff and patient's relatives, but requires fast logistics.